Panbela Therapeutics Inc. (NASDAQ:PBLA) finished Thursday with an addition of $0.11 to close at $0.35, an upside of 46.39 percent. An average of 5,022,440 shares of common stock have been traded in the last five days. There was a fall of -$0.0240 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,328,715 shares traded, while the 50-day average volume stands at 542,430.
PBLA stock has decreased by -55.61% in the last month. The company shares reached their 1-month lowest point of $0.2028 on 09/22/22. With the stock rallying to its 52-week high on 02/22/22, shares of the company touched a low of $0.24 and a high of $2.40 in 52 weeks. It has reached a new high 7 times so far this year and lost -79.48% or -$1.3751 in price. In spite of this, the price is down -85.21% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
The quick ratio of Panbela Therapeutics Inc. for the three months ended March 30 was 0.60, and the current ratio was 0.60, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $11000.0 compared to revenue of $10.01 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Panbela Therapeutics Inc.’s return on assets was -277.80%.
For the three-month period that ended March 30, Panbela Therapeutics Inc. had $5.19 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$22.13 million in the quarter, while revenues of -$3.67 million were grew 90.1%. The analyst consensus anticipated Panbela Therapeutics Inc.’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.27, a -8.00% surprise. For the quarter, EBITDA amounted to -$21.29 million. At the end of the quarter ending March 30, Panbela Therapeutics Inc.’s stock balance sheet showed total liabilities of 11.39 million. Shareholders own equity worth $20.77 million.
From a technical analysis perspective, let’s take a brief look at Panbela Therapeutics Inc. (PBLA) price momentum. RSI 9-day as of the close on 22 September was 38.18%, suggesting the stock is Neutral, with historical volatility in this time frame at 459.31%.
As of today, PBLA’s price is $0.3520 -6.33% or -$0.0240 from its 5-day moving average. PBLA is currently trading -55.06% lower than its 20-day SMA and -79.94% lower than its 100-day SMA. However, the stock’s current price level is -69.13% below the SMA50 and -79.71% below the SMA200.
The stochastic %K and %D were 7.25% and 6.74%, respectively, and the average true range (ATR) was 0.1511. With the 14-day stochastic at 19.15% and the average true range at 0.1363, the RSI (14) stands at 35.63%. The stock has reached -0.1017 on the 9-day MACD Oscillator while the 14-day reading was at -0.1722.
What is PBLA’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $6.00, with a median target of $5.50. Taking a look at these predictions, the average price target given by analysts for Panbela Therapeutics Inc. (PBLA) stock is $5.50.